Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether the proposed first line treatment for
falciparum malaria in this region (sulfadoxine-pyrimethamine + artesunate) would be no worse
a treatment for vivax malaria that the standard vivax treatment of chloroquine. In areas
where vivax and falciparum malaria co-exist misdiagnosis of vivax malaria as falciparum is
not unlikely; it is important to know whether adequate treatment will be received in these
cases.